Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid. 2022

Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
Drug Metabolism and Pharmacokinetics (Y.Z., C.C, E.M.J., Z.Y., H.S.), Discovery Toxicology (S.-J.C., L.A.), Discovery Pharmaceutics (X.-Q.C.), and Veterinary Sciences (D.J.S., H.D.), Bristol Myers Squibb Company, Princeton, New Jersey; and Drug Metabolism and Pharmacokinetics (S.-J.C.), Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Bangalore, India.

Farnesoid X receptor (FXR) is a nuclear receptor known to markedly alter expression of major transporters and enzymes in the liver. However, its effects toward organic anion transporting polypeptides (OATP) 1B1 and 1B3 remain poorly characterized. Therefore, the present study was aimed at determining the effects of chenodeoxycholic acid (CDCA), a naturally occurring FXR agonist, on OATP1B expression in cynomolgus monkeys. Multiple administrations of 50 and 100 mg/kg of CDCA were first shown to significantly repress mRNA expression of SLCO1B1/3 approximately 60% to 80% in monkey livers. It also suppressed cytochrome P450 (CYP)7A1-mRNA and induced OSTα/β-mRNA, which are well known targets of FXR and determinants of bile acid homeostasis. CDCA concomitantly decreased OATP1B protein abundance by approximately 60% in monkey liver. In contrast, multiple doses of 15 mg/kg rifampin (RIF), a pregnane X receptor agonist, had no effect on hepatic OATP1B protein, although it induced the intestinal P-glycoprotein and MR2 proteins by ∼2-fold. Moreover, multiple doses of CDCA resulted in a steady ∼2- to 10-fold increase of the OATP1B biomarkers coproporphyrins (CPs) in the plasma samples collected prior to each CDCA dose. Additionally, 3.4- to 11.2-fold increases of CPI and CPIII areas under the curve were observed after multiple administrations compared with the single dose and vehicle administration dosing groups. Taken together, these data suggest that CDCA represses the expression of OATP1B1 and OATP1B3 in monkeys. Further investigation of OATP1B downregulation by FXR in humans is warranted, as such downregulation effects may be involved in bile acid homeostasis and potential drug interactions in man. SIGNIFICANCE STATEMENT: Using gene expression and proteomics tools, as well as endogenous biomarker data, for the first time, we have demonstrated that OATP1B expression was suppressed and its activity was reduced in the cynomolgus monkeys following oral administration of 50 and 100 mg/kg/day of chenodeoxycholic acid (CDCA), a Farnesoid X receptor agonist, for 8 days. These results lead to a better understanding of OATP1B downregulation by CDCA and its role on bile acid and drug disposition.

UI MeSH Term Description Entries
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D002635 Chenodeoxycholic Acid A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones. Chenic Acid,Chenodeoxycholate,Chenodiol,Gallodesoxycholic Acid,Chenique Acid,Chenix,Chenofalk,Chenophalk,Henohol,Quenobilan,Quenocol,Sodium Chenodeoxycholate,Acid, Chenic,Acid, Chenique,Acid, Chenodeoxycholic,Acid, Gallodesoxycholic,Chenodeoxycholate, Sodium
D003306 Coproporphyrins Porphyrins with four methyl and four propionic acid side chains attached to the pyrrole rings. Elevated levels of Coproporphyrin III in the urine and feces are major findings in patients with HEREDITARY COPROPORPHYRIA.
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
October 2020, Drug metabolism and disposition: the biological fate of chemicals,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
May 2015, The Journal of pharmacology and experimental therapeutics,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
January 2003, Placenta,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
October 2006, Molecular pharmacology,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
April 2015, Drug metabolism and pharmacokinetics,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
November 2003, European journal of clinical investigation,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
March 2019, Pharmacology & therapeutics,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
March 2016, Molecular pharmaceutics,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
January 2016, Xenobiotica; the fate of foreign compounds in biological systems,
Yueping Zhang, and Shen-Jue Chen, and Cliff Chen, and Xue-Qing Chen, and Sagnik Chatterjee, and David J Shuster, and Heather Dexter, and Laura Armstrong, and Elizabeth M Joshi, and Zheng Yang, and Hong Shen
April 2002, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!